The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InMadrigal Pharmaceuticals (MDGL) has significantly expanded its metabolic dysfunction-associated steatohepatitis (MASH) pipeline by securing exclusive global licensing rights to six preclinical siRNA programs. This strategic agreement was made with Suzhou Ribo Life Science Co. Ltd. The deal involves an upfront payment of $60 million, alongside potential milestone payments that could reach up to $4.4 billion upon achieving specified development and commercial objectives. This move aims to develop innovative combination therapies, leveraging Madrigal's recently approved drug Rezdiffra, to enhance MASH treatment outcomes. The expansion reinforces Madrigal's commitment to strengthening its MASH franchise and addressing the serious liver disease with advanced therapeutic solutions. This proactive step positions Madrigal for potential long-term growth and market leadership in MASH treatment.